This discordance in HER2 expression between primary tumour and MRD has clinical significance, as a study by Apostolaki et al. [262] demonstrated that the presence of HER2 mRNA in CTCs enriched from patient blood after they had undergone adjuvant chemotherapy was associated with decreased DFS. Here, ERBB2 is linked to neoplasm.